@article{ref1,
title="Can we win the war on obesity with pharmacotherapy?",
journal="Expert review of clinical pharmacology",
year="2016",
author="Gotthardt, J.D. and Bello, N.T.",
volume="9",
number="10",
pages="1289-1297",
abstract="INTRODUCTION: Obesity is a major health concern for several countries. The United States (U.S.) has arguably led the world in the percentage of overweight and/or obese per capita for several decades. As a result, numerous FDA-approved pharmacotherapeutic options are available for the long-term treatment of obesity. Although most of these medications have been on the U.S. market for a few years and have demonstrated efficacy for long-term weight loss in clinical trials, the impact of these medications on obesity in the U.S. has yet to be realized. Areas covered: We will review and evaluate why pharmacotherapy for obesity has not produced a meaningful reduction in the number of overweight and obese adults in the U.S. Expert commentary: Several obstacles, such as adverse drug effects, poor insurance coverage, not treating obesity as a chronic disease, and availability of other weight loss alternatives, has resulted in poor performance of pharmacotherapy for obesity in the U.S. market. © 2016 Informa UK Limited, trading as Taylor & Francis Group.<p /><p>Language: en</p>",
language="en",
issn="1751-2433",
doi="10.1080/17512433.2016.1232164",
url="http://dx.doi.org/10.1080/17512433.2016.1232164"
}